A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Project description

Simple outpatient treatment for acid reflux disease

Gastroesophageal reflux disease is a disorder of the digestive system caused by defects in the lower oesophageal sphincter, resulting in heartburn, regurgitation, and reflux of gastric acid and digestive enzymes. Very common in the EU, this condition is currently treated with symptomatic medications, which do not address the underlying cause. This EU-funded project aims to introduce minimally invasive outpatient treatment for this disease using injectable bulking agent to support endoscopic remodelling of the sphincter for a long-term cure. The procedure will involve injection of biocompatible polymethylmethacrylate microspheres to provide a scaffold for fibrovascular tissue ingrowth in the affected area. The first phase of the project will establish market strategy as well as the draft for the development plan.

Field of science

• /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
• /natural sciences/biological sciences/biochemistry/biomolecules/proteins/enzymes

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ASCENTX MEDICAL EUROPE LIMITED

Address

Unit 6 Queens Yard, White Post Lane
E95EN London
United Kingdom

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 50 000